Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data

Johnson & Johnson is chasing hefty immunology rivals with a plaque psoriasis nod from the FDA—and fast-growing sales—to show for it so far. Not content with that, Tremfya is eyeing psoriatic arthritis, and it might now have the data to get it there.